Pembrolizumab is a checkpoint inhibitor - an antibody that blocks PD-1, a receptor on T-cells that acts as a brake on immune activity. Many cancers exploit that brake to avoid immune attack. Blocking it releases the restraint and allows the immune system to recognise and destroy the tumour. It has produced durable responses in cancers that previously had very poor outcomes. Its side effects follow directly from the mechanism: an immune system with the brakes off can attack healthy tissue anywhere in the body.
Follow the plan your oncology team gave you. This guide contains no doses.
Immune-related adverse events
These are unlike chemotherapy side effects. They are autoimmune inflammation, they can affect essentially any organ, and they are treated with steroids rather than by waiting.
The commoner ones:
- Skin - rash and itching, usually early
- Bowel - colitis causing diarrhoea, abdominal pain and blood or mucus
- Thyroid - overactive then underactive, often needing lifelong levothyroxine - see levothyroxine
- Liver - hepatitis, usually found on blood tests before symptoms
- Lungs - pneumonitis causing breathlessness and a dry cough
- Pituitary and adrenal glands - causing profound fatigue, low blood pressure and collapse, which can be life-threatening
- Pancreas - occasionally causing sudden type 1 diabetes
Less commonly, the kidneys, heart, eyes, joints and nerves.
What to report, and how quickly
The rule your team will give you is to report anything new rather than deciding whether it matters.
Contact your oncology team the same day for diarrhoea that is increasing or contains blood, new or worsening breathlessness or cough, severe fatigue, yellowing of the skin or eyes, severe abdominal pain, a widespread rash, unexplained thirst and passing urine frequently, dizziness or collapse, or any new visual or neurological symptom.
Early treatment with steroids usually settles these. Delayed treatment is what leads to serious harm - colitis progressing to perforation, pneumonitis to respiratory failure.
Do not take anti-diarrhoeal medicine for immunotherapy diarrhoea without advice. Slowing the bowel in immune colitis can make things considerably worse - see loperamide.
Effects can be delayed
This is the part most often missed. Immune-related events can appear weeks or months after the last dose, long after treatment has finished.
Someone presenting to a GP or emergency department a year later may not mention immunotherapy, and the clinician may not ask. That delay costs time when the treatment is straightforward.
Carry your immunotherapy alert card and show it to anyone treating you, including out of hours and in A and E, for at least a year after finishing. Say the word "immunotherapy" - it changes the differential diagnosis immediately.
Steroids do not undo the benefit
People sometimes worry that treating an immune side effect with steroids will cancel the anti-cancer effect.
The evidence is broadly reassuring: treating immune-related events appropriately does not appear to negate the benefit. Withholding treatment for fear of that is the greater risk.
Steroid courses may be prolonged and tapered slowly, which brings their own considerations - see coming off steroid tablets safely.
Before starting
Existing autoimmune conditions need discussion, since they can flare. So does a history of organ transplant, where checkpoint inhibitors can precipitate rejection.
Baseline bloods include thyroid, liver, kidney and glucose, and these are repeated before each cycle - which is how several of these problems are picked up before symptoms.
Tell your team about every medicine and supplement you take.
How it is given
By infusion, typically every three or six weeks, in a day unit. Infusion reactions are uncommon and usually mild.
Treatment often continues for up to two years where it is working, and responses can persist long after it stops - which is one of the genuinely distinctive features of this class.
Vaccines
Inactivated vaccines including flu and COVID are recommended. Live vaccines are generally avoided during treatment.
Check with your team before any vaccination - see infection risk on immune-suppressing medicines.
Combination immunotherapy
Pembrolizumab is sometimes given with chemotherapy, or with another checkpoint inhibitor such as ipilimumab, which blocks a different brake.
Combining two checkpoint inhibitors increases both the response rate and the rate of immune-related side effects, which are more frequent and more severe. If you are on a combination, the threshold for reporting a new symptom should be lower still, and the alert card matters more.
Reporting
Report side effects through the Yellow Card scheme as well as to your team - see how Yellow Card works. This is a relatively new class of medicine and the long-term picture is still being assembled from exactly those reports.
The Conditions section covers more on what medicines are prescribed for - Dicycloverine: Antispasmodics for IBS Cramping is closely related to this one.